Page last updated: 2024-10-25

cl 387785 and ARPKD

cl 387785 has been researched along with ARPKD in 1 studies

CL 387785: structure in first source
N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.

Research Excerpts

ExcerptRelevanceReference
"Contrary to other murine models of ARPKD, overexpression and apical mislocalization of EGFR were not detected in the PCK rats."1.32Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. ( Avner, ED; Frost, P; Harris, PC; Qian, Q; Sweeney, WE; Torres, VE; Wang, X, 2004)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Torres, VE1
Sweeney, WE1
Wang, X1
Qian, Q1
Harris, PC1
Frost, P1
Avner, ED1

Other Studies

1 other study available for cl 387785 and ARPKD

ArticleYear
Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
    Kidney international, 2004, Volume: 66, Issue:5

    Topics: Aminoquinolines; Aniline Compounds; Animals; Cyclic AMP; Disease Models, Animal; ErbB Receptors; Fem

2004